Human immunodeficiency virus (HIV)-related renal
Results. A total of 89 patients were included, 55 of whom diseases are the third leading cause of end-stage renal were alive at the time of data collection. The mean age was disease (ESRD) among African Americans aged 20 to 64 44.6 years (range, 22.7 to 66.9 years), 74.2% were male, and 83.2% patients were African Americans. While only 45.9% of years old [1] . While antiretroviral medications have been patients undergoing renal biopsy were diagnosed with HIVeffective in slowing the progression of HIV-associated associated nephropathy (HIVAN), the majority of patients nephropathy (HIVAN) [2] [3] [4] [5] [6] [7] , it is projected that due to who had not undergone biopsy carried the clinical diagnosis the increasing numbers of patients living with acquired of HIVAN (69.8%, P ϭ 0.03). Of the cohort, 19.7% tested immunodeficiency syndrome (AIDS), the number of hepatitis B surface antigen positive, and 67.1% had reactive antibody tests for hepatitis C. Patients with hepatitis C were HIV-infected patients reaching ESRD will increase exmore likely to have experienced intravenous drug use as a risk ponentially over the next decade (abstract; Schwartz EJ behavior for HIV acquisition (OR 8.2; 95% CI 2.39, 27.9; P ϭ et al, J Am Soc Nephrol 2000: 11:165a, 2000) . 0 .001] and to be older (OR 1.1 per year of age; 95% CI 1.02, Prior to the use of highly active antiretroviral therapy 1.2; P ϭ 0.01). A total of 60.7% of patients were receiving (HAART), HIV-infected ESRD patients had a high antiretroviral medication at last follow-up. Among patients alive and receiving antiretroviral medications at the time of data mortality rate with mean survival times of 3.0 months collection, absolute CD4ϩ count rose (268 vs. 339 cells/mL, P ϭ [8] , 4.47 months [9] , and 11.0 [10] months. Among HIV-0.03), while among patients alive, but not receiving antiretroviral infected ESRD patients, higher absolute CD4ϩ lymphocyte counts have been associated with prolonged survival [10, 11] . Subsequently, an observational cohort study has While conclusions regarding the absolute efficacy of anti-Data analysis retroviral medications on mortality from these studies are Demographic and clinical characteristics, including limited by either small sample size [12] or lack of patient age at initiation of dialysis, gender, race, risk behaviors level data on use of antiretroviral medications [13] , these for HIV acquisition, duration of HIV infection prior to data are compelling. They suggest a temporal relationinitiation of dialysis, and etiology of renal disease, were ship between availability of protease inhibitors and imdescribed for patients overall and for patients alive at provement in survival that may be similar to that seen the time of data collection (between April 2001 and July among patients with normal kidney function [14, 15] . 2001).
Little information is available on dosing and variations in
The frequency with which patients underwent diagefficacy of antiretroviral medications among HIV-infected nostic renal biopsy prior to the institution of renal repatients with . Further, little is known about placement therapy was calculated. The types and frethe demographic and clinical characteristics of the popuquency of histologic lesions identified among patients lation of patients who are HIV-infected and currently undergoing renal biopsy were compared to the presumed receiving renal replacement therapy. Given the expected etiology (herein termed clinical diagnosis) of renal disexponential increase in the number of HIV-infected paease among patients not undergoing renal biopsy. tients receiving renal replacement therapy, this study Initial (at incidence to ESRD) and most current absowas undertaken to describe the clinical characteristics lute CD4ϩ lymphocyte count and HIV RNA level were and antiretroviral dosing patterns among HIV-infected described for all patients and subsequently for patients patients receiving hemodialysis to better understand the alive at the time of data collection stratified on whether clinical needs of this population.
or not patients were receiving antiretroviral therapy. Due to the nonnormal distribution of HIV RNA levels, METHODS comparison of these values were performed on log-trans-Study subjects and data collection formed measurements. Information on antiretroviral medi-This retrospective cohort study describes the epidemication use and dose were described for all patients and ology, clinical history, and clinical practice patterns of for patients alive at the time of data collection. The use all HIV-infected patients with ESRD receiving renal reof antiretroviral medication among patients with current placement therapy (hemodialysis and peritoneal dialysis)
CD4 lymphocyte counts Ն200, 201 to 500, and Ͼ500 at Duke University Medical Center, Metrohealth Medicells were compared. Among patients alive at the time of cal Center, Mount Sinai Medical Center, Indiana Univerdata collection, most current absolute CD4ϩ lymphocyte sity Medical Center, and San Francisco General Hospicount and HIV RNA level were compared for patients tal. These sites are represented by members of the Renal receiving and not receiving antiretroviral medication. Working Group of the AIDS Clinical Trials Group.
The frequency of a positive hepatitis C antibody and All patients with documented HIV infection who behepatitis B surface antigen were calculated among all gan receiving renal replacement therapy (hemodialysis patients in whom these tests had been performed. Assoor peritoneal dialysis) regardless of the etiology of renal ciations between a positive hepatitis C antibody or hepadisease (e.g., HIVAN, other HIV-related renal disease, titis B surface antigen were tested using logistic regresdiabetes mellitus, hypertension) between January 1,1998 sion. Clinical and demographic variables of interest were and January 1, 2001 were included. This period of time initially tested in both univariate and multivariable modwas chosen to provide a sample representative of patients els. The frequency of types of hemodialysis vascular actreated during the HAART era. Patients were identified cess was described for all patients receiving hemodialysis for study through both the nephrologist and infectious at the time of data collection or at the time of their death. diseases physicians at each institution. Information on Erythropoietin dose and hematocrit were described for patient demographics, medical history, dialysis treatment patients alive at the time of data collection. characteristics, and medication use and dosing (at the Continuous and categoric variables between subgroups time of the last clinical encounter immediately preceding of interest were compared using either the Wilcoxon data collection) was abstracted from each patient's clinirank sum or Student t test and Fisher's exact or chical chart and dialysis record. This study was approved square tests, as appropriate. The paired t test was used by the Institutional Review Board of each institution.
to compare those continuous variables measured repeat-Because of the study design and methods, the Instituedly within individual patients (such as HIV RNA level tional Review Board at each institution waived the reand CD4ϩ lymphocyte count). All P values reported quirement for consent. Therefore, no patient was conare two-sided, and all confidence intervals reported are tacted. All information was abstracted directly from the 95% CIs. All analyses were performed using Stata (vermedical record, and data was collected without ability to subsequently link it back to the individual. sion 7.0, College Station, TX, USA). 
years). The
A total of 60.7% (54 of 89 patients) were receiving average length of time between first documented HIV antiretroviral medications at the time of data collection infection and start of renal replacement therapy was 5.6 or the time of last follow-up. Among patients whose years (range, Ϫ4.5 to 15.2 years). Seven patients were most current CD4 lymphocyte count was Ͻ200, 67.7% diagnosed with HIV infection following the start of renal (21 of 31 patients) were receiving antiretroviral medications. The proportion of patients receiving antiretroviral replacement therapy with six of the seven patients being AR is antiretroviral status at time of data collection a Median (25th and 75th percentiles) b P ϭ 0.03 comparing initial CD4ϩ count to current CD4ϩ count among patients receiving antiretrovirals medications c P ϭ 0.11 comparing initial CD4ϩ count to current CD4ϩ count among patients not receiving antiretrovirals medications d P ϭ 0.02 comparing initial HIV RNA level to current HIV RNA level among patients receiving antiretrovirals medications e P ϭ 0.11 comparing initial HIV RNA level to current HIV RNA level among patients not receiving antiretrovirals medications medications was unchanged among patients with CD4 cess (47.5%, N ϭ 30) ( Table 5 ). Twelve (40%) of the lymphocyte counts of 200 to 500 and Ͼ500 cells at 71.4% 30 patients using a tunneled catheter as vascular access (15 of 21 patients) and 48.6% (18 of 37 patients), respechad another access that was available but not in use due tively (P ϭ 0.14). At the time of their last clinical encounto the need for access maturation or surgical revision ter, patients alive at the time of data collection were (nine patients had a native fistula and three patients had more likely to be receiving antiretroviral medications a synthetic graft). than patients who were deceased (Table 1) (70.7 vs. 41.9%, P ϭ 0.009). Among patients alive at the time of DISCUSSION data collection, use of antiretroviral medications was This study describes the clinical and demographic charassociated with an increase in absolute CD4ϩ lymphoacteristics, the dosing regimens for antiretroviral medicacyte count over the study period (268 vs. 339 cells/mL, tions, and the frequency of renal biopsy of HIV-infected P ϭ 0.03). Among patients alive but not receiving antiretpatients receiving renal replacement therapy in five medroviral medications absolute CD4ϩ count did not change ical centers. Further, it describes a significant proportion (389 vs. 392 cells/mL, P ϭ 0.11) ( Table 3 ). The period of HIV-infected dialysis patients who are coinfected with of time between first and current CD4ϩ count measureboth HIV-1 and hepatitis C. ments were similar for groups receiving and not receiving While slightly less than one half of patients who underantiretroviral medications (2.3 vs. 2.3 years, P ϭ 0.93).
went renal biopsy prior to the institution of dialysis had Among patients alive and receiving antiretroviral medithe histologic diagnosis of HIVAN, a significantly greater cations at the time of data collection, HIV RNA level proportion of patients who did not undergo renal biopsy fell (36,088 vs. 13,182 copies/mL, P ϭ 0.02), while among were stated in the medical record to have HIVAN as patients alive but not receiving antiretroviral medications the "clinical" diagnosis. Given that noninvasive tests are HIV RNA level did not change (Table 3 ) (P ϭ 0.11).
unable to distinguish between HIVAN and other lesions Among patients receiving antiretroviral medications, [19] , this disparity suggests an overestimation of the frethere were significant variations in dosing regimens of quency of HIVAN and an underestimation of other renal individual medications. Among patients receiving nucleolesions that the HIV-infected patient may experience. side reverse transcriptase inhibitors, the greatest varia-While biases may be introduced in the selection of pation in regimen existed in the dosing of lamivudine and tients to undergo renal biopsy, the proportion of patients zidovudine. Lamivudine was prescribed to 36 patients with with HIVAN among the subgroup patients biopsied in a 12-fold range in dosage from 25 mg/day to 300 mg/day this study is similar to the previously described propor-( Table 4 and Fig. 1A) . Zidovudine was prescribed to 11 tions among patients receiving clinical care [19, 20] and patients with a 14-fold range in dosage from 100 mg patients undergoing autopsy [21] . While a number of these three times a week to 300 mg twice a day (Table 4 and histologic lesions may be treated empirically, among cer- Fig. 1B) . Variations in dosing regimen were similarly tain patients, disease-specific therapy may aid in slowing seen among nonnucleoside reverse transcriptase inhibithe progression of their renal disease. More aggressive tors and protease inhibitors. diagnostic testing may be warranted.
Hemodialysis modality and access
While this study is limited in its ability to assess the efficacy of antiretroviral agents on immune reconstitu-Five patients were undergoing peritoneal dialysis while tion among dialysis patients, it suggests that absolute the vast majority of patients (84 of 89) were undergoing CD4ϩ counts may be improved among dialysis patients hemodialysis. Among patients undergoing hemodialysis, a tunneled catheter was the most frequent vascular ac-receiving these agents as compared with those who do a Nine patients had a native arteriovenous fistula and three patients had a synthetic arteriovenous graft antiretroviral medications in this study, the natural history of viral suppression, and issues of follow-up and noncompliance. Of note, the comparison of CD4 lymphocyte count and HIV RNA level at baseline and at the time of data collection among patients alive at the time of data collection may be affected by the exclusion of patients who died during the course of the study. While this introduces the possibility of informative censoring, included. This and prior studies have not assessed the barriers to prescription among HIV-infected patients receiving renal replacement therapy, which will be essential in understanding the efficacy of these agents overall not. This is consistent with prior studies demonstrating the efficacy of antiretroviral agents in immune reconsti-and among subgroups of eligible or compliant patients. There were substantial variations in dosing regimens tution [12, 22] and prolonged survival [10, 12] . Interestingly, HIV RNA levels fell only slightly between the time for antiretroviral medications among patients in this study. The variation of dosing of protease inhibitors and patients began dialysis and the period of data collection. While this may be a function of limited power afforded nonnucleoside reverse transcriptase inhibitors may be related in part to the variations required by the use of by this sample, it may further be a reflection of the variation in dosing regimen seen among patients receiving concurrent medications (other antiretroviral, antimyco-bacterial, or antiepilieptic medications). For instance, data are unable to examine those factors that might result in a survival bias, selecting patients with a decreased lower doses of ritonavir (e.g., 100 to 200 mg/day) may be used as a "booster" agent in conjunction with other mortality risk prior to or following the beginning of renal replacement therapy. While this analysis has attempted protease inhibitors to permit their prescription at smaller doses or decreased frequency. Among the nucleoside to minimize this bias through the inclusion of patients based on initiation of dialysis following January 1, 1998, reverse transcriptase inhibitors, however, there was considerable variation in the dosing of lamivudine and zido-the measurements of current clinical parameters such as CD4ϩ lymphocyte count and HIV RNA level were strati-vudine. The impact of this variation in dosing on outcomes cannot be determined from these data but may fied on the basis of vital status to obviate the effect of include the effects of both underdosing with decreased any preterminal events on the measures of these prevalent therapeutic benefit and subadequate viral suppression characteristics among patients currently receiving dialysis. in some cases and overdosing and the potential exposure to increased toxicity related to the medications. As few CONCLUSION studies adequately establish the pharmacokinetics and This study describes the clinical and demographic suggested dosing regimens for these agents among pacharacteristics as well as the clinical practice patterns of tients with decreased renal function and patients receivantiretroviral prescription among HIV-infected patients ing dialysis [23] [24] [25] [26] [27] [28] , this remains an area of essential receiving renal replacement therapy in the post-HAART research toward establishing the most efficacious treatera. Based on these data, additional questions in the care ment regimens for HIV-infected patients on dialysis.
of the HIV-infected ESRD patient should be examined. While the use of antiretroviral medications may be HIV-infected patients with renal disease who undergo impacted by a number of factors such as potential to renal biopsy have differences in the distribution of histoadhere to therapy, patient interest in therapy, risk of logic and clinical diagnoses as compared with patients toxicity and drug interactions, current clinical practice not undergoing biopsy. From a health service perspecguidelines suggest that therapy be initiated among pative, this likely represents a substantial rate of misdiagnotients who are either symptomatic with CD4 lymphocyte sis. At the patient level, more aggressive diagnostic evalcounts Ͼ200 cells or asymptomatic patients with CD4 uation using renal biopsy may result in the ability to lymphocyte counts of Ͻ200 cells [29] . This study demonprovide directed treatment. The impact of this on outstrated that a significant proportion of patients with CD4 comes is not known. Further, the mechanism and impact count Ͻ200 cells were not receiving therapy at the time of the substantial rate of coinfection with hepatitis C of data collection. As these data do not allow the examination of other more subjective factors that affect the suggests that this may become an important focus of individualized decision to begin therapy, they suggest future research as outcomes for these patients improve. that antiretroviral therapy may be underutilized among Finally, the wide variation in dosing of antiretroviral patients who may receive the greatest benefit. medications suggests that there are subgroups of patients This study demonstrated that a high proportion of who are not receiving the appropriate dose to maximally HIV-infected patients receiving dialysis are coinfected suppress viral replication or minimize drug toxicity. As with hepatitis C. While estimates vary, studies of prevalittle information is available on the pharmacokinetics lent dialysis patients estimate that between 8% and 36% of many of these medications and the number of HIVof patients in North America have a test positive for infected patients receiving renal replacement therapy hepatitis C [30, 31]. Because of the cross-sectional design is expected to grow at an exponential rate (abstract; of this study, it cannot be determined if these patients Schwartz EJ et al, J Am Soc Nephrol 11:165a, 2000), were exposed to hepatitis C before or after beginning investigation of dosing and efficacy of these medications renal replacement therapy. Because of the association in this population is essential. Based on the projected between hepatitis C infection and intravenous drug use, growth of the population of HIV-infected patients with it is likely that a number of patients were coinfected prior ESRD, this study provides epidemiologic and clinical to the initiation of renal replacement therapy. Future information that describes the clinical needs of this popuresearch will be required to determine the effect of colation. infection with HIV-1 and hepatitis C on the rate of progression of chronic kidney disease as well as on hepatic ACKNOWLEDGMENTS and mortality outcomes in this unique group of patients. 
